A Placebo Controlled, Double Blind, Randomised, 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2011
At a glance
- Drugs Eprotirome (Primary)
- Indications Hypercholesterolaemia
- Focus Biomarker; Therapeutic Use
- Sponsors Karo Bio
- 12 Nov 2008 New trial record.